About: B-Cell Targeted Therapies in Autoimmune Cytopenias and Thrombosis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: B-Cell Targeted Therapies in Autoimmune Cytopenias and Thrombosis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	B-Cell Targeted Therapies in Autoimmune Cytopenias and Thrombosis
Creator	Matta, B Matta, Bassem Nayfe, R Nayfe, Rabih Taher, Ali Taher, • Uthman, I Uthman, Imad
source	PMC
abstract	Ever since the advent of Rituximab and subsequently the emergence of other compounds targeting B cells, a cornucopia of medical applications have been found for this family of compounds. After their establishment as standard of care in many conditions such as rituximab in lymphoma and rheumatoid arthritis, they have been progressively found to aid in the treatment of many other conditions. This area constituted a fertile area of research in the past 12 years. Physicians have investigated the B-cell depleting agents use in cases of autoimmune hematologic cytopenias such as immune thrombocytopenia, Evans syndrome, cold and warm autoimmune hemolytic anemia, and other thrombophilic disorders such as the antiphospholipid syndrome and thrombocytopenic purpura. This chapter presents a historical perspective reviewing the various studies that have been published in this field. In addition, it offers a current assessment of the evidence regarding the use of B-cell depleting agents in the aforementioned conditions.
has issue date	2013-10-29(xsd:dateTime)
bibo:doi	10.1007/978-3-0348-0706-7_11
has license	no-cc
sha1sum (hex)	b3d177bd58d442986c25eebc466b7db43032c9ba
schema:url	https://doi.org/10.1007/978-3-0348-0706-7_11
resource representing a document's title	B-Cell Targeted Therapies in Autoimmune Cytopenias and Thrombosis
has PubMed Central identifier	PMC7123699
schema:publication	Drugs Targeting B-Cells in Autoimmune Diseases
resource representing a document's body	covid:b3d177bd58d442986c25eebc466b7db43032c9ba#body_text
is schema:about of	named entity 'conditions' named entity 'Thrombosis' named entity 'WARM AUTOIMMUNE HEMOLYTIC ANEMIA' named entity 'AID' named entity 'PERSPECTIVE' named entity 'LYMPHOMA' named entity 'EVIDENCE' named entity 'AREA' named entity 'STUDIES' named entity 'AUTOIMMUNE' named entity 'ESTABLISHMENT' named entity 'PUBLISHED' named entity 'CYTOPENIAS' named entity 'studies' named entity 'area' named entity 'compounds' named entity 'compounds' named entity 'B-Cell' named entity 'cytopenias' named entity 'rheumatoid arthritis' named entity 'lymphoma' named entity 'cornucopia' named entity 'standard of care' named entity 'B-cell' named entity 'thrombocytopenic purpura' named entity 'Cytopenias' named entity 'Autoimmune' named entity 'ITP' named entity 'ITP' named entity 'lymphoma' named entity 'standard treatment' named entity 'IVIG' named entity 'autoantibodies' named entity 'human immunodeficiency virus infection' named entity 'FDA' named entity 'ADAMTS' named entity 'phase II trial' named entity '100 %' named entity 'chemotherapy regimen' named entity 'Neunert' named entity 'antibody' named entity 'thrombus' named entity 'purpura' named entity 'rituximab' named entity 'immunosuppressive agents' named entity 'rituximab' named entity 'B-cell' named entity 'cold-type' named entity 'neurologic' named entity 'antiphospholipid' named entity 'FDA' named entity '1,000,000' named entity 'R-CHOP' named entity 'Sallah' named entity 'chemotherapy' named entity 'rituximab' named entity 'targeted therapies' named entity 'platelet count' named entity 'mycophenolate mofetil' named entity 'steroid' named entity 'clinical symptoms' named entity 'week of gestation' named entity 'congenital' named entity 'histological' named entity 'AIHA' named entity 'aPL' named entity 'Stasi' named entity 'immunosuppression' named entity 'AIHA' named entity 'Helicobacter pylori' named entity '5.5' named entity 'autoantibodies' named entity 'inflammatory' named entity 'standard of care' named entity 'standard treatment' named entity 'varicella zoster'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software